Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study optimizing bevacizumab with FOLFOX/OXXEL in metastatic colorectal cancer
2011-004997-27Phase 3Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in colorectal cancer (CRC) and metastatic colon cancer (mCRC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Objective response rate. Started Mar 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2011-004997-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004997-27.